Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 3:10 AM
Ignite Modification Date:
2025-12-25 @ 3:10 AM
NCT ID:
NCT06077305
Eligibility Criteria:
Inclusion Criteria:
Study 1:
1. Age ≥ 18 years old.
2. Acute ischemic stroke within 7 days of onset.
3. Sign an informed consent form.
Study 2:
1. Age ≥ 18 years old.
2. Ischemic stroke during recovery period, within 30 days to 1 year of onset.
3. Sign an informed consent form.
Study 3:
1. Age ≥ 18 years old.
2. Within 3 years, there are characteristic lesions of cerebral small vessel disease on head MRI or CT, and they meet at least one of the following criteria:
1. Paraventricular or deep white matter hyperintensities, Fazekas total score ≥ 2;
2. Paraventricular or deep white matter hyperintensities, Fazekas total score=1, and at least two vascular risk factors (hypertension, hyperlipidemia, diabetes, current smoking, obesity, history of coronary heart disease, history of stroke).
3. Paraventricular or deep white matter hyperintensities, Fazekas total score=1, with ≥ 1 lacune.
4. New recent subcortical small infarcts.
3. Sign an informed consent form.
Exclusion Criteria:
Study 1:
1. Cerebral hemorrhage and subarachnoid hemorrhage within 3 months of onset.
2. There are untreated cerebral vascular malformations or untreated aneurysms (diameter\>3mm).
3. Confirmed neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Parkinson's syndrome, etc.
4. A mental illness diagnosed according to the DSM-V diagnostic criteria.
5. There are clear diagnoses of non-vascular white matter lesions, such as multiple sclerosis, adult white matter dysplasia, metabolic encephalopathy, etc.
6. Unable to cooperate in completing follow-up visits due to geographical or other reasons.
7. The patient also participated in other clinical trials.
Study 2:
1. Cerebral hemorrhage and subarachnoid hemorrhage within 3 months of onset.
2. There are untreated cerebral vascular malformations or untreated aneurysms (diameter\>3mm).
3. Confirmed neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Parkinson's syndrome, etc.
4. A mental illness diagnosed according to the DSM-V diagnostic criteria.
5. There are clear diagnoses of non-vascular white matter lesions, such as multiple sclerosis, adult white matter dysplasia, metabolic encephalopathy, etc.
6. Unable to cooperate in completing follow-up visits due to geographical or other reasons.
7. The patient also participated in other clinical trials.
Study 3:
1. Cerebral hemorrhage and subarachnoid hemorrhage within 3 months of onset.
2. There are untreated cerebral vascular malformations or untreated aneurysms (diameter\>3mm).
3. Confirmed neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Parkinson's syndrome, etc.
4. A mental illness diagnosed according to the DSM-V diagnostic criteria.
5. There are clear diagnoses of non-vascular white matter lesions, such as multiple sclerosis, adult white matter dysplasia, metabolic encephalopathy, etc.
6. Unable to cooperate in completing follow-up visits due to geographical or other reasons.
7. The patient also participated in other clinical trials.
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT06077305
Study Brief:
Protocol Section:
NCT06077305